

Meeting Report

25th Meeting of the Technical Advisory Group on Immunization and Vaccine-Preventable Diseases in the Western Pacific Region



26–29 July 2016
Manila, Philippines



25TH MEETING OF THE TECHNICAL ADVISORY GROUP ON IMMUNIZATION AND
VACCINE-PREVENTABLE DISEASES IN THE WESTERN PACIFIC REGION
26-29 July 2016, Manila, Philippines

WORLD HEALTH ORGANIZATION
REGIONAL OFFICE FOR THE WESTERN PACIFIC

MEETING REPORT

**25th Meeting of the Technical Advisory Group on Immunization and
Vaccine-preventable Diseases**

Convened by:

WORLD HEALTH ORGANIZATION
REGIONAL OFFICE FOR THE WESTERN PACIFIC

Manila, Philippines

26–29 July 2016

Not for sale

Printed and distributed by:

World Health Organization
Regional Office for the Western Pacific
Manila, Philippines

October 2016

NOTE

The views expressed in this report are those of the participants of the 25th Meeting of the Technical Advisory Group on Immunization and Vaccine-preventable Diseases in the Western Pacific Region and do not necessarily reflect the policies of the conveners.

The Expanded Programme on Immunization of the WHO Regional Office for the Western Pacific would like to thank Japan Voluntary Contribution, Gavi, the Vaccine Alliance, and the United States Centers for Disease Control and Prevention for providing financial support for the meeting, including the production of this report.

This report has been prepared by the World Health Organization Regional Office for the Western Pacific for Member States in the Region and for those who participated in the 25th Meeting of the Technical Advisory Group on Immunization and Vaccine-Preventable Diseases in the Western Pacific Region in Manila, Philippines, from 26 to 29 July 2016.

1. CONTENTS

SUMMARY.....	8
1. INTRODUCTION.....	9
1.1 Meeting organization	9
1.2 Meeting objectives	9
2. PROCEEDINGS	9
2.1 Opening session	9
2.2 Update on Implementation of Global Vaccine Action Plan (GVAP)	10
2.3 Update from Strategic Advisory Group of Experts.....	10
2.4 Sustaining polio-free status and implementation of polio endgame strategies.....	11
2.4.1 Global update	11
2.4.2 Regional update.....	11
2.4.3 Polio laboratory network and environmental surveillance update	12
2.4.4 Global Polio Eradication Initiative outbreak response.....	12
2.4.5 Country presentation – outbreak of circulating vaccine-derived poliovirus	12
2.4.6 Trivalent oral polio vaccine bivalent oral polio vaccine switch and inactivated polio vaccine supply	13
2.4.7 Country presentations.....	13
2.4.8 Laboratory containment	14
2.5 Hepatitis B accelerated control	14
2.5.1 Global/regional update	14
2.6 Japanese encephalitis (JE) accelerated control.....	15
2.6.1 Global/regional update	15
2.6.2 Western Pacific Region JE laboratory network	15
2.6.3 JE outbreak in the Philippines.....	15
2.6.4 Ethics Review Committee update (targets, strategies and timeliness)	16
2.7 Measles and rubella elimination.....	16
2.7.1 Global update	16

2.7.2	Regional overview and draft regional strategy.....	16
2.7.3	Country presentations.....	17
2.7.4	Proposed strategy for immunization	19
2.7.5	Country presentation – epidemiologic surveillance	20
2.7.6	Proposed strategy for epidemiologic surveillance.....	20
2.7.7	Country presentation – laboratory support.....	21
2.7.8	Proposed strategy for laboratory support	21
2.7.9	Country presentation – outbreak preparedness and response.....	21
2.7.10	Proposed strategy for outbreak preparedness and response	23
2.7.11	Regional Verification Commission.....	23
2.7.12	National Verification Commission	23
2.7.13	Proposed strategy for other strategic areas.....	24
2.8	Maternal and Neonatal Tetanus Elimination (MNTE).....	24
2.8.1	Regional Update.....	24
2.9	Strengthening immunization systems (including strengthening routine immunization programme).....	24
2.9.1	Global perspective on strengthening routine immunization programme: Global Routine Immunization Strategies Practices	24
2.9.2	Closing gaps: addressing inequity in the regional context.....	25
2.9.3	Achieving high and equitable immunization in urban settings	25
2.9.4	Life-course approach, school-based immunization – New Zealand.....	26
2.9.5	Vaccine security: implementation plan for Effective Vaccine Management (EVM) in Papua New Guinea.....	27
2.9.6	Diphtheria in the Philippines.....	27
2.9.7	Strengthening evidence-based decision-making	28
2.9.8	Lessons learnt: functional National Immunization Technical Advisory Groups	28
2.9.9	Data quality in Western Pacific Region countries: overview, challenges and opportunities	28
2.9.10	Data quality assessment and data improvement plan.....	29
2.9.11	Lessons to be learnt from implementing an electronic immunization registry	29
2.9.12	Regional vaccine regulatory update.....	29

2.9.13	Global and regional vaccine safety update.....	30
2.10	Introduction of New and Underutilized Vaccine (NUVI).....	30
2.10.1	Global/Regional NUVI update.....	30
2.10.2	Surveillance networks.....	30
2.10.3	Western Pacific Regional rotavirus and invasive bacterial diseases laboratory networks.....	31
2.10.4	Country presentation – pneumococcal conjugate (PCV) introduction.....	31
2.10..	Dengue vaccine update	32
2.10.6	Safety surveillance in dengue vaccine introduction: the Philippines experience.....	32
2.11	Implementation of Western Pacific Regional Framework for Global Vaccine Action Plan.....	32
2.11.1	Regional update	32
2.12	Partners Meeting	33
3.	CONCLUSIONS AND RECOMMENDATIONS.....	34
3.1	Conclusions.....	34
3.1.1	Sustaining polio-free status and implementation of polio endgame strategies.....	34
3.1.2	Hepatitis B accelerated control	35
3.1.3	Japanese encephalitis (JE) accelerated control.....	35
3.1.4	Measles and rubella elimination.....	35
3.1.5	Maternal and neonatal tetanus elimination.....	36
3.1.6	Strengthening routine immunization systems-equity and sustainability	36
3.1.7	Strengthening evidence-based immunization decision-making	37
3.1.8	Strengthening routine immunization – data quality	38
3.1.9	Strengthening vaccine safety surveillance and regulatory capacity	38
3.1.10	Evidence-based introduction of new vaccines	38
3.1.11	Dengue	39
3.2	Recommendations for Member States	39
3.2.1	Sustaining polio-free status and implementation of polio endgame strategies.....	39
3.2.2	Hepatitis B accelerated control	40
3.2.3	Japanese encephalitis (JE) accelerated control.....	40
3.2.4	Measles and rubella elimination.....	41

3.2.5	Maternal and neonatal tetanus elimination.....	42
3.2.6	Strengthening routine immunization systems-equity and sustainability	42
3.2.7	Strengthening evidence-based immunization decision-making	43
3.2.8	Strengthening routine immunization – data quality	43
3.2.9	Strengthening vaccine safety surveillance and regulatory capacity	43
3.2.10	Evidence-based introduction of new vaccines	44
3.2.11	Dengue	44
3.3	Recommendations for WHO Secretariat.....	45
3.3.1	Sustaining polio-free status and implementation of polio endgame strategies.....	45
3.3.2	Hepatitis B accelerated control	45
3.3.3	Japanese encephalitis (JE) accelerated control.....	45
3.3.4	Measles and rubella elimination.....	45
3.3.5	Strengthening routine immunization systems – equity and sustainability	46
3.3.6	Strengthening evidence-based immunization decision-making	46
3.3.7	Strengthening vaccine safety surveillance and regulatory capacity	46
3.3.8	Evidence-based introduction of new vaccines	47

Annex 1. List of participants

Annex 2. Meeting programme

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26891

